SuperworthSAB Biotherapeutics market cap SABS
Share price times shares outstanding: what the whole company sells for, since 2021.
- Today, Oct 23, 2026
- $258.4M
- Highest close in our data
- $456.5M
- Nov 2021
SAB Biotherapeutics is worth $258.4M at the close on Oct 23, 2026, at $2.84 a share.
That is up 719% over the last year and up 121% over five years.
Its highest close in our data was $456.5M in Nov 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $258.4M | $170M | $354.8M | +44% |
| 2025 | $180M | $10.5M | $190M | +366% |
| 2024 | $38.6M | $21.8M | $43.2M | +7% |
| 2023 | $36M | $17.7M | $51.8M | +42% |
| 2022 | $25.4M | $25.4M | $320.4M | −93% |
| 2021 | $339.5M | $117M | $456.5M | n/a |
Against its peers
Companies in Biotechnology nearest SAB Biotherapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| SABSSAB Biotherapeutics | $258.4M |
| PLXProtalix BioTherapeutics | $205.5M |
| MGTXMeiraGTx | $884.6M |
| VCELVericel | $2.2B |
| ADMAAdma Biologics | $2.4B |
| Peer median | $1.5B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on SAB Biotherapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.